Search hospitals

>

Washington

>

Spokane

Cancer Care Northwest - Spokane South

Claim this profile

Spokane, Washington 99202

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Pancreatic Cancer

Conducts research for Cancer

Conducts research for Ovarian Cancer

262 reported clinical trials

5 medical researchers

Photo of Cancer Care Northwest - Spokane South in SpokanePhoto of Cancer Care Northwest - Spokane South in SpokanePhoto of Cancer Care Northwest - Spokane South in Spokane

Summary

Cancer Care Northwest - Spokane South is a medical facility located in Spokane, Washington. This center is recognized for care of Breast Cancer, Lung Cancer, Pancreatic Cancer, Cancer, Ovarian Cancer and other specialties. Cancer Care Northwest - Spokane South is involved with conducting 262 clinical trials across 271 conditions. There are 5 research doctors associated with this hospital, such as Chanh T. Huynh, Rafael Santana-Davila, MD, Kristine Rinn, MD, and Janice N. Kim.

Area of expertise

1

Breast Cancer

Global Leader

Cancer Care Northwest - Spokane South has run 51 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
PR positive
2

Lung Cancer

Global Leader

Cancer Care Northwest - Spokane South has run 44 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
Stage III

Top PIs

Clinical Trials running at Cancer Care Northwest - Spokane South

Ovarian Cancer

Breast Cancer

Colorectal Cancer

Breast cancer

Esophageal cancer

Prostate Cancer

Stomach Cancer

Bladder Cancer

Esophageal Cancer

Pancreatic Cancer

Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Surgical Procedures

for Reducing Ovarian Cancer Risk

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

Recruiting

1 award

N/A

Image of trial facility.

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Cancer Care Northwest - Spokane South?